DELPHAI, AI Agent for Predicting Drug Response and Resistance

Patient-derived organoids preserve critical tumor features and drug sensitivity patterns that mirror patient clinical responses, enabling single-cell RNA sequencing analysis of drug responses. Analyzing these perturbation data presents significant computational challenges in predicting cellular responses while maintaining biological interpretability. We developed DELPHAI (Deep ExplainabLe Predictive Human-organoid based AI), an AI agent that integrates single-cell perturbation prediction with mechanistic analysis using large language models. We designed a comprehensive benchmarking framework evaluating methods in both computational embedding and reconstructed gene expression spaces. Applied to glioblastoma organoids treated with temozolomide, optimal transport combined with principal component analysis outperformed baseline methods in capturing population dynamics. DELPHAI correctly identified DNA alkylation as the mechanism of action without prior drug knowledge and recommended combination therapies aligning with clinical trials. These results demonstrate DELPHAPs ability to translate single-cell perturbation data into actionable therapeutic insights, representing a significant advance toward Al-driven precision medicine in cancer treatment.